7 drug(s) with this reaction
3,982 total reports
Hospitalisation has been reported as an adverse reaction across 7 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 3,982 adverse event reports mention hospitalisation in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with hospitalisation, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have hospitalisation listed in their FDA adverse event reports, sorted by report count:
In addition to hospitalisation, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
7 drug(s) manufactured by Abbvie Inc have hospitalisation listed in their FDA adverse event reports: VENETOCLAX, PANCRELIPASE, UPADACITINIB, RISANKIZUMAB-RZAA, DIVALPROEX SODIUM, and others.
There are a combined 3,982 reports of hospitalisation across 7 Abbvie Inc drug(s) in the FDA adverse event database.